The SURMOUNT-1 trial (*NEJM*, 2022) showed participants on 15mg Tirzepatide lost an average of 22.5% of their body weight at 72 weeks -- roughly 5 percentage points more than Semaglutide achieves
Related Reading Injection Wegovy Injection Tirzepatide Injection Semaglutide Injection Ozempic Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims
Your GP can assess whether the benefits of Ozempic outweigh the side effects in your individual case and may consider: Adjusting the dose or titration schedule Investigating other potential causes of bloating (such as small intestinal bacterial overgrowth, coeliac disease, or irritable bowel syndrome) Referring to a gastroenterologist if symptoms are atypical or severe Considering alternative diabetes medications if Ozempic is not well-tolerated Patient safety is paramount, and open communication with healthcare providers ensures that any concerning symptoms are appropriately evaluated whilst maintaining effective diabetes management
Most patients with proteinuric kidney disease, irrespective of having type 2 diabetes, should also be considered candidates for SGLT-2 inhibitor therapy
